REG - Allergy Therapeutics - Notice of 2025 Annual General Meeting

Allergy TherapeuticsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260106:nRSF7235Na&default-theme=true

RNS Number : 7235N  Allergy Therapeutics PLC  06 January 2026

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Notice of 2025 Annual General Meeting

 

06 January 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy immunotherapies, has
today published its Notice of Annual General Meeting following publication of
the Annual Report and Accounts for the year ended 30 June 2025 (the "2025
Accounts"). The Notice of Annual General Meeting has been posted to
shareholders of the Company (the "Shareholders") today and is available to
view on, and download from, the Company's website at
https://www.allergytherapeutics.com/investors/shareholder-services/agm-information/
(https://www.allergytherapeutics.com/investors/shareholder-services/agm-information/)
.

Approval of new appointments to Board

 

The Company is seeking shareholder approval to appoint two additional
directors to the Board, as detailed below, each of whom brings decades of
expertise in their respective fields. The Board believes these appointments
will directly support the Group's current explorations of a potential dual
primary listing on the Hong Kong Stock Exchange, alongside its existing
listing on the London Stock Exchange's AIM market, and the ambition to expand
Allergy Therapeutics' presence in Asia and become a global leader in allergy
treatments. The proposed appointments of the additional directors remain
subject to completion of customary due diligence and will be effective upon
receipt of shareholder approval at the Annual General Meeting. A further
announcement will be made in due course, as required.

 

Helge Weiner-Trapness - Executive Director and Chief Strategy Officer

 

Until 2025, Mr Weiner-Trapness held the role of Vice Chairman, Global Banking,
at HSBC, one of the world's largest financial organisations which is
dual-listed on the London Stock Exchange and the Hong Kong Stock Exchange.
Prior to this, he was a Founding Partner of Hong Kong-based Quintus Partners,
an independent financial advisory firm offering investment banking, strategic
advisory and capital raising, particularly in the US and Asia. With earlier,
senior positions at Barclays Bank, Asia Pacific Land, JP Morgan Securities and
Goldman Sachs, Mr Weiner-Trapness brings more than 30 years of experience
across some of the world's biggest investment banks in the US and Asia.

 

In the newly created role of Chief Strategy Officer, Mr Weiner-Trapness will
drive the Group's long-term growth strategy, including corporate development,
partnership strategy and portfolio prioritisation, as Allergy Therapeutics
advances its next-generation pipeline and explores opportunities to deliver on
its global ambitions.

 

Lawrence Allen Wang - Non-Executive Director

 

Lawrence Allen Wang is the Chief Financial Officer of Adicon (HKG: 9860) one
of China's leading independent clinical laboratory service providers. Mr Wang
led and executed the company's $88 million share financing in 2020, bringing
in an international, blue-chip investor syndicate and, in 2023, successfully
listed the company on the Hong Kong Stock Exchange. Later that year the
company qualified for entry into the Hong Kong Stock Exchange's Stock Connect
mutual market access programme, that links the Hong Kong Stock Exchange with
Mainland China's two main exchanges. Mr Wang has more than 20 years of
healthcare and investment experience. He qualified as a Doctor of Medicine
from Boston University School of Medicine in 2003 and has an MBA from MIT
Sloan School of Management.

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

 

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries and branches in nine major European countries and via
distribution agreements in an additional four countries. For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com/)
.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFZGGMMKLGVZZ



            Copyright 2019 Regulatory News Service, all rights reserved